TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from CardieX ( (AU:CDX) ) is now available.
CardieX Limited reported a significant decrease in revenue for the fiscal year ending June 2025, with a 67% drop compared to the previous year, primarily due to the early conclusion of the Clinichain clinical trial. Despite a 10% increase in revenue excluding Clinichain, the company faced a 95% increase in net loss, attributed to reduced revenue and increased marketing expenses for the new Pulse device. The company’s financial position showed improvement with increased current assets and reduced liabilities, supported by successful share issuances and financing activities. However, cash flow from operations was negative, reflecting the challenges in revenue generation and cost management.
More about CardieX
CardieX Limited operates in the medical technology industry, focusing on the development and commercialization of devices and solutions for cardiovascular health management. The company is known for its innovative products such as the Pulse device and has a market focus on improving patient outcomes through advanced health monitoring technologies.
Average Trading Volume: 447,789
Technical Sentiment Signal: Sell
Current Market Cap: A$16.5M
For an in-depth examination of CDX stock, go to TipRanks’ Overview page.